Conshohocken, PA, December 16, 2019 --(PR.com
)-- 3Sixty Pharma Solutions LLC, www.3sixtypharma.com, last week announced the successful submission to FDA of its first Investigational New Drug (IND) Application on behalf of one of its start-up biotech clients. This news comes on the heels of the formal organization in 2018 of 3Sixty Pharma Solutions’ 360Start-Up arm, which is committed to accelerating and supporting product development efforts, boosting commercialization and marketing operations, and driving product launch for start-up and growing life sciences companies.
“This marks the culmination of more than a year’s work with this particular start-up biotech company, and months of building infrastructure, expertise, and capacity within our company to be able offer this important service to our clients,” said Dalfoni Banerjee, 3Sixty Pharma Solutions’ Principal Consultant & CEO. Banerjee went on to say, “There are several additional FDA filings we’ll support over the next six months and beyond.”
About 3Sixty Pharma Solutions
3Sixty Pharma Solutions is a privately-held, US-based life sciences consulting firm whose mission is to accelerate and support the development of medicines and therapies, boost operations efficiency, and drive product launch for start-up and established pharmaceutical, biotechnology, and medical device companies. 3Sixty Pharma Solutions is comprised of a network of experts who’ve honed their skills in large and start-up biopharma companies - and who now offer their expertise to facilitate the success of our clients. Our core capabilities are science, communications, and project management and our niche is the ability to channel clients’ pain-points out of the critical path of their routine activities into the hands of seasoned experts who are bolstered by a robust process structure that assures quality and timeliness. We’re here for our clients when they need nimble support and experienced helping hands.
Further information about 3Sixty Pharma Solutions can be found at www.3sixtypharma.com.